🚀 VC round data is live in beta, check it out!
Laboratorios Richmond Valuation Multiples
Discover revenue and EBITDA valuation multiples for Laboratorios Richmond and similar public comparables like Bioton, Verrica Pharmaceuticals, Pyxis Oncology, Actinogen Medical and more.
Laboratorios Richmond Overview
About Laboratorios Richmond
Laboratorios Richmond SACIF is an Argentine pharmaceutical company that develops and manufactures quality pharmaceutical products. The products are offered to physicians, pharmacists, health institutions and patients. The product offered by the group include antiviral, oncologic and oncohematologic, cardiovascular, and neuropsychiatric products; and hospital products.
Founded
1959
HQ
Employees
N/A
Website
Sectors
Financials (FY)
EV
$266M
Laboratorios Richmond Financials
Laboratorios Richmond reported last fiscal year revenue of $91M and EBITDA of $24M.
In the same fiscal year, Laboratorios Richmond generated $56M in gross profit, $24M in EBITDA, and $2M in net income.
Laboratorios Richmond P&L
In the most recent fiscal year, Laboratorios Richmond reported revenue of $91M and EBITDA of $24M.
Laboratorios Richmond expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | — | XXX | $91M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $56M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 62% | XXX | XXX | XXX |
| EBITDA | — | XXX | $24M | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 27% | XXX | XXX | XXX |
| EBIT Margin | — | XXX | 24% | XXX | XXX | XXX |
| Net Profit | — | XXX | $2M | XXX | XXX | XXX |
| Net Margin | — | XXX | 2% | XXX | XXX | XXX |
| Net Debt | — | — | $155M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Laboratorios Richmond Stock Performance
Laboratorios Richmond has current market cap of $99M, and enterprise value of $266M.
Market Cap Evolution
Laboratorios Richmond's stock price is $1.23.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $266M | $99M | 0.4% | XXX | XXX | XXX | $0.03 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialLaboratorios Richmond Valuation Multiples
Laboratorios Richmond trades at 2.9x EV/Revenue multiple, and 11.0x EV/EBITDA.
Laboratorios Richmond Financial Valuation Multiples
As of April 10, 2026, Laboratorios Richmond has market cap of $99M and EV of $266M.
Equity research analysts estimate Laboratorios Richmond's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Laboratorios Richmond has a P/E ratio of 44.5x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $99M | XXX | $99M | XXX | XXX | XXX |
| EV (current) | $266M | XXX | $266M | XXX | XXX | XXX |
| EV/Revenue | — | XXX | 2.9x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | 11.0x | XXX | XXX | XXX |
| EV/EBIT | — | XXX | 12.3x | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 4.7x | XXX | XXX | XXX |
| P/E | — | XXX | 44.5x | XXX | XXX | XXX |
| EV/FCF | — | XXX | (7.0x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Laboratorios Richmond Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Laboratorios Richmond Margins & Growth Rates
Laboratorios Richmond's revenue in the last fiscal year grew by 38%.
Laboratorios Richmond Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | 38% | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 27% | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | (14%) | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 13% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 3% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 38% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Laboratorios Richmond Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Bioton | XXX | XXX | XXX | XXX | XXX | XXX |
| Verrica Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Pyxis Oncology | XXX | XXX | XXX | XXX | XXX | XXX |
| Actinogen Medical | XXX | XXX | XXX | XXX | XXX | XXX |
| Vistin Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Laboratorios Richmond M&A Activity
Laboratorios Richmond acquired XXX companies to date.
Last acquisition by Laboratorios Richmond was on XXXXXXXX, XXXXX. Laboratorios Richmond acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Laboratorios Richmond
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialLaboratorios Richmond Investment Activity
Laboratorios Richmond invested in XXX companies to date.
Laboratorios Richmond made its latest investment on XXXXXXXX, XXXXX. Laboratorios Richmond invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Laboratorios Richmond
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Laboratorios Richmond
| When was Laboratorios Richmond founded? | Laboratorios Richmond was founded in 1959. |
| Where is Laboratorios Richmond headquartered? | Laboratorios Richmond is headquartered in Argentina. |
| Is Laboratorios Richmond publicly listed? | Yes, Laboratorios Richmond is a public company listed on Buenos Aires Stock Exchange. |
| What is the stock symbol of Laboratorios Richmond? | Laboratorios Richmond trades under RICH ticker. |
| When did Laboratorios Richmond go public? | Laboratorios Richmond went public in 2017. |
| Who are competitors of Laboratorios Richmond? | Laboratorios Richmond main competitors are Bioton, Verrica Pharmaceuticals, Pyxis Oncology, Actinogen Medical. |
| What is the current market cap of Laboratorios Richmond? | Laboratorios Richmond's current market cap is $99M. |
| What is the current revenue of Laboratorios Richmond? | Laboratorios Richmond's last fiscal year revenue is $91M. |
| What is the current EV/Revenue multiple of Laboratorios Richmond? | Current revenue multiple of Laboratorios Richmond is 2.9x. |
| Is Laboratorios Richmond profitable? | No, Laboratorios Richmond is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.